华森制药(002907) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥194,061,643.88, a decrease of 7.42% compared to the same period last year, and a year-to-date revenue of ¥561,689,616.37, down 12.96% year-on-year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥20,873,546.27, a decline of 37.07% year-on-year, with a year-to-date net profit of ¥72,847,006.41, down 18.55%[8]. - The company's basic earnings per share for Q3 2022 was ¥0.0520, down 37.12% year-on-year, with diluted earnings per share also at ¥0.0520[7]. - Total operating revenue for the third quarter was ¥561,689,616.37, a decrease of 12.94% compared to ¥645,340,755.20 in the previous year[35]. - The net profit for the period was 9,136,788.75, a decrease of 41.1% compared to 15,547,817.36 in the previous period[38]. - The total comprehensive income attributable to the parent company's owners was 73,279,409.35, down from 89,412,584.34 in the previous period[42]. - The total operating profit was 82,354,030.96, a decrease of 21.5% from 104,903,485.57 in the previous period[38]. Cash Flow and Liquidity - The company's cash flow from operating activities for the year-to-date period was ¥77,571,456.00, an increase of 28.93% year-on-year[7]. - The net cash received from operating activities increased by 40.23% to ¥21,975,422.91, primarily due to higher government subsidies received[19]. - The total cash inflow from operating activities was 513,646,935.93, compared to 537,271,102.83 in the previous period[45]. - The cash outflow for purchasing goods and services was 114,008,774.73, down from 159,198,374.92 in the previous period[45]. - The cash flow from investment activities was -55,641,234.56, slightly worse than -50,761,485.99 in the previous period[45]. - The cash and cash equivalents at the end of the period were 422,039,676.26, down from 465,232,335.71 at the end of the previous period[45]. - The net increase in cash and cash equivalents improved by 50.98% to -¥7,928,170.15, influenced by increased government subsidies and reduced tax payments[22]. Research and Development - The company increased its R&D investment by 32.76% year-on-year, with R&D expenses rising by 53.39% compared to the same period last year[8]. - R&D expenses increased by 53.39% to ¥38,905,107.64 compared to ¥25,363,574.05 in the same period last year, primarily due to increased investment in R&D[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,814,894,636.19, reflecting a 2.45% increase from the end of the previous year[7]. - The company's total liabilities decreased to ¥496,022,630.08 from ¥505,563,562.44, indicating improved financial health[34]. - Non-current assets increased to ¥894,207,851.78 from ¥877,385,749.10, reflecting ongoing investments in long-term resources[32]. - Accounts receivable increased by 32.12% to ¥216,126,422.05 compared to the end of the previous year, primarily due to an increase in customer receivables[17]. - Inventory levels were reported at ¥122,559,224.60, slightly down from ¥127,437,191.78, suggesting effective inventory management[32]. Other Financial Metrics - The company's gross profit margin decreased due to a 22.69% decline in production volume, leading to increased unit production costs[8]. - Financial expenses surged by 354.21% to ¥6,663,004.62, attributed to decreased interest income from bank deposits and increased interest expenses from convertible bonds[18]. - Other income rose by 175.77% to ¥12,936,740.52, mainly due to increased government subsidies received during the period[18]. - The fair value change income increased by 183.23% to ¥1,518,648.22, mainly due to the increase in financial products[18]. - The company experienced a 94.33% increase in credit impairment losses to -¥3,141,569.14, primarily due to an increase in accounts receivable[18]. - The tax expense decreased by 41.23% to ¥9,136,788.75, mainly due to a reduction in total profit and increased R&D expense deductions[18]. Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[35]. - The company plans to independently operate the "Quchang" brand of orlistat capsules, which is currently in the market introduction phase[7]. Reporting Information - The third quarter report of Chongqing Huasen Pharmaceutical Co., Ltd. is unaudited[49]. - The report was released on October 26, 2022[49].